Artivion’s (AORT) “Market Outperform” Rating Reiterated at JMP Securities

Artivion (NYSE:AORT)‘s stock had its “market outperform” rating restated by research analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $33.00 price target on the stock. JMP Securities’ target price suggests a potential upside of 10.29% from the stock’s current price.

AORT has been the topic of several other research reports. Needham & Company LLC reiterated a “buy” rating and set a $34.00 price target on shares of Artivion in a research note on Monday. Stifel Nicolaus raised their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Oppenheimer boosted their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $31.80.

Artivion Price Performance

Shares of NYSE:AORT opened at $29.92 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.25 billion, a PE ratio of -1,496.00 and a beta of 1.75. The firm’s 50 day moving average price is $27.58 and its 200-day moving average price is $26.14. Artivion has a twelve month low of $16.48 and a twelve month high of $30.45.

Insider Buying and Selling

In related news, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the sale, the vice president now owns 33,503 shares in the company, valued at $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,377 shares of company stock worth $682,356. 8.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AORT. Tidal Investments LLC lifted its stake in Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after purchasing an additional 134,642 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after buying an additional 125,668 shares during the period. Perceptive Advisors LLC lifted its stake in shares of Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after acquiring an additional 124,725 shares during the last quarter. Sio Capital Management LLC purchased a new position in Artivion during the 3rd quarter valued at $3,226,000. Finally, Barclays PLC grew its position in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after acquiring an additional 54,996 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.